April 28, 2017 / 10:38 AM / 4 months ago

CORRECTED-BRIEF-Genmab gets EMA for Darzalex for Relapsed or Refractory Multiple Myeloma

(Corrects headline to add dropped words 'Relapsed or Refractory Multiple Myeloma')

April 28 (Reuters) - GENMAB

* GENMAB ANNOUNCES EUROPEAN MARKETING AUTHORIZATION FOR DARZALEX® (DARATUMUMAB) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA

* SAYS GENMAB WILL RECEIVE MILESTONE PAYMENTS TOTALING USD 48 MILLION FROM JANSSEN BIOTECH, INC

* SAYS THESE MILESTONE PAYMENTS WERE INCLUDED IN FINANCIAL GUIDANCE ISSUED BY GENMAB ON FEBRUARY 22, 2017 AND THEREFORE THERE IS NO CHANGE TO COMPANY'S FINANCIAL GUIDANCE FOLLOWING THIS APPROVAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below